---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000049"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:58:23.503663+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma appoints new CEO, advances ABP-450 biosimilar path, reports $10.4M cash

## Summary
- Rob Bancroft appointed President and CEO effective April 29, 2025; also joins Board. Former CEO Marc Forth remains on Board.
- Pursuing 351(k) biosimilar pathway for ABP-450 with BOTOX as reference; plans BPD Type 2a meeting with FDA in H2 2025.
- Cash and equivalents of $10.4M at March 31, 2025; expected to fund operations through Q4 2025 and planned FDA meeting.
- NYSE American accepted compliance plan; granted until August 3, 2026 to regain continued listing standards.

## SEC filing metadata
- accession: 0001837607-25-000049
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/0001837607-25-000049-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000049/aeon-20250514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000049
- JSON: https://secwatch.observer/filing/0001837607-25-000049.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000049.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.